Drug Profile

BCN CP01

Alternative Names: BCN-CP01; GLPG-5201

Latest Information Update: 23 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CellPoint Bio
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Chronic lymphocytic leukaemia

Most Recent Events

31 Dec 2024 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Second-line therapy or greater) in Spain (IV), prior to December 2024
30 Oct 2024 Galapagos plans to file IND for phase I/II EUPLAGIA-1 trial for Chronic lymphocytic leukaemia to US FDA in early 2025
30 Oct 2024 Galapagos plans a phase II trial for Chronic lymphocytic leukaemia (Second-line therapy or greater) in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com